

# U.S. Biosimilars Market Landscape

As of May 27, 2022

Class	Supportive Care			Oncology			TNF Blockers			Insulin	Ophthalmology
<b>Molecule</b>	Filgrastim	Epoetin	Pegfilgrastim	Rituximab	Bevacizumab	Trastuzumab	Infliximab	Etanercept	Adalimumab	Insulin Glargine	Ranibizumab
<b>Innovator</b>	Neupogen (Amgen)	Epogen/Procrit (Amgen / JnJ)	Neulasta (Amgen)	Rituxan (Genentech)	Avastin (Genentech)	Herceptin (Genentech)	Remicade (JnJ)	Enbrel (Amgen)	Humira (AbbVie)	Lantus (Sanofi)	Lucentis (Genentech)
<b>Launched</b> Manufacturer Launch Date	Zarxio Sandoz Sep 2015	Retacrit Pfizer/Vifor Nov 2018	Fulphila Viartis Jul 2018	Truxima Teva Nov 2019	Mvasi Amgen Jul 2019	Kanjinti Amgen Jul 2019	Inflectra Pfizer Nov 2016	Ongoing litigation forecasted launch 2028/2029	Biosimilars referencing Humira will launch in 2023	INT Semglee Viartis Nov 2021	Interchangeability designation
	Nivestym Pfizer Oct 2018		Udenyca Coherus Jan 2019	Ruxience Pfizer Jan 2020	Zirabev Pfizer Jan 2020	Ogivri Viartis Nov 2019	Renflexis Organon Jul 2018				
			Ziextenzo Sandoz Nov 2019	Riabni Amgen Jan 2021	AlymSYS Amneal April 2022	Trazimera Pfizer Feb 2020	Avsola Amgen Jul 2020	Erelzi Sandoz Aug 2016	Amjevita Amgen Sep 2016	Hulio Viartis Jul 2020	
			Nyvepria Pfizer Dec 2020			Herzuma Teva Mar 2020	Ixifi Pfizer Dec 2014	Eticovo Samsung Aug 2019	INT Cyltezo BI Aug 2017	Yusimry Coherus Dec 2021	
<b>Approved</b> Manufacturer FDA Approval Date	Releuko Amneal March 2022		Fylnetra Amneal May 2022			Ontruzant Organon Apr 2020			Hyrimoz Sandoz Oct 2018		
									Hadlima Organon Jul 2019		
									Abrilada Pfizer Nov 2019		
										Rezvoglar Eli Lilly Dec 2021	
										Byooviz Biogen Sep 2021	